Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, has entered into a contract manufacturing agreement with ImmunoGen, Inc.

Laureate Pharma will manufacture for ImmunoGen the huC242 antibody used in the production of their huC242-DM4 Tumour-Activated Prodrug (TAP) compound, now in phase II clinical testing. Terms of the manufacturing agreement were not disclosed.

"ImmunoGen is well known for its proprietary TAP technology, which uses tumour-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells," said Robert J. Broeze, Ph.D., President and Chief Executive Officer of Laureate Pharma. "Laureate Pharma has an established track record in the manufacture of protein based biopharmaceuticals. We are pleased that ImmunoGen chose us to manufacture their antibody and we are excited to be working with them."

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support